GlassScriptPhysician profile
Andrew K Cole
NPI 1669465886
$2,746.68
in general payments reported to CMS, 2019-2025
31 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $148 · 2021: $219 · 2022: $553 · 2023: $139 · 2024: $671 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $326.87 | 2019-2022 | |
| Amgen INC. | $213.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $194.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.55 | 2021-2024 | |
| Novo Nordisk INC | $142.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $138.88 | 2019 | |
| Pfizer INC. | $135.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $134.83 | 2024 | |
| Phathom Pharmaceuticals, INC. | $134.25 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $132.87 | 2019-2022 | |
| Exact Sciences Corporation | $119.39 | 2025 | Cologuard Collection Kit |
| Braeburn INC. | $88.98 | 2025 | Brixadi |
| Alkermes, INC. | $86.57 | 2024 | Vivitrol |
| Regeneron Healthcare Solutions, INC. | $85.14 | 2024 | Dupixent |
| Mylan Specialty L.P. | $84.50 | 2024 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $78.21 | 2021 | |
| Abbvie INC. | $71.58 | 2019-2024 | |
| Lilly USA, LLC | $65.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $60.12 | 2023 | |
| Abbott Laboratories | $48.43 | 2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.04 | 2019 | |
| Corcept Therapeutics | $31.66 | 2019 | |
| Daiichi Sankyo INC. | $31.43 | 2021 | |
| Merck Sharp & Dohme LLC | $30.28 | 2019 | |
| Idorsia Pharmaceuticals US INC | $30.22 | 2023 | Quviviq |
| Merz Pharmaceuticals, LLC | $19.71 | 2025 | Xeomin |
| Celgene Corporation | $18.94 | 2019 | |
| Astellas Pharma US INC | $16.60 | 2019 | |
| Amarin Pharma, INC. | $14.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.98 | 2021 | |
| Grifols USA, LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.